Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
Cancer Research
|
November 3, 2001
Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts
M W Deininger, S A Vieira, Y Parada, et al.
Leukemia
|
April 6, 2016
A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
M Wagle, A M Eiring, M Wongchenko, et al.
Leukemia
|
February 28, 2015
A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia
D W Woessner, A M Eiring, B J Bruno, et al.
Leukemia
|
August 19, 2017
Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib
W Qiang, O Antelope, M S Zabriskie, et al.
British Journal of Cancer
|
April 22, 2010
Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo
S A Bright, A M McElligott, J W O'Connell, et al.
Leukemia
|
January 26, 2007
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
D W Sherbenou, M J Wong, A Humayun, et al.
Leukemia
|
July 11, 2008
High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia
J W Tyner, M M Loriaux, H Erickson, et al.
Leukemia
|
August 3, 2016
Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy
J S Khorashad, S K Tantravahi, D Yan, et al.
Leukemia
|
July 24, 2015
β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
A M Eiring, J S Khorashad, D J Anderson, et al.
Leukemia
|
December 10, 2015
Age-related mutations and chronic myelomonocytic leukemia
C C Mason, J S Khorashad, S K Tantravahi, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
Cancer Research
|
November 3, 2001
Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts
M W Deininger, S A Vieira, Y Parada, et al.
Leukemia
|
April 6, 2016
A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
M Wagle, A M Eiring, M Wongchenko, et al.
Leukemia
|
February 28, 2015
A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia
D W Woessner, A M Eiring, B J Bruno, et al.
Leukemia
|
August 19, 2017
Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib
W Qiang, O Antelope, M S Zabriskie, et al.
British Journal of Cancer
|
April 22, 2010
Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo
S A Bright, A M McElligott, J W O'Connell, et al.
Leukemia
|
January 26, 2007
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
D W Sherbenou, M J Wong, A Humayun, et al.
Leukemia
|
July 11, 2008
High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia
J W Tyner, M M Loriaux, H Erickson, et al.
Leukemia
|
August 3, 2016
Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy
J S Khorashad, S K Tantravahi, D Yan, et al.
Leukemia
|
July 24, 2015
β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
A M Eiring, J S Khorashad, D J Anderson, et al.
Leukemia
|
December 10, 2015
Age-related mutations and chronic myelomonocytic leukemia
C C Mason, J S Khorashad, S K Tantravahi, et al.
Page
of 4